Stiolto Respimat (tiotropium bromide/olodaterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). It comes with an inhaler for breathing the drug into your ...

Stiolto Respimat (tiotropium bromide and olodaterol) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD). Stiolto Respimat can cause side effects that range from mild to ...

Stiolto Respimat (tiotropium bromide/olodaterol) is an inhaled medication for the treatment of chronic obstructive pulmonary disease (COPD), bronchitis, and emphysema. However, it is not indicated for ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) ...

In addition to the new exacerbation data, the indication for Stiolto Respimat has been revised. The Food and Drug Administration (FDA) has approved updated labeling for Stiolto Respimat (tiotropium ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the ...

In the PHYSACTO trial, exercise capacity was measured by the length of time people with COPD could walk in an Endurance Shuttle Walking Test, which measures how far someone can walk at a standard ...

Boehringer Ingelheim announced new data from a Phase 3b study of Stiolto Respimat (tiotropium, olodaterol) in which treatment with Stiolto Respimat led to significant improvements in SGRQ total score ...

Please provide your email address to receive an email when new articles are posted on . Stiolto Respimat helped improve quality of life and lung function in patients with COPD, according to study ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily Stiolto™ Respimat ® (tiotropium bromide and olodaterol) Inhalation Spray. It has been approved ...